MODULATION OF OPIOID AND NMDA RECEPTOR MRNA BY RIBOZYMES

核酶对阿片类药物和 NMDA 受体 mRNA 的调节

基本信息

  • 批准号:
    2700904
  • 负责人:
  • 金额:
    $ 26.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1996
  • 资助国家:
    美国
  • 起止时间:
    1996-06-01 至 1999-04-30
  • 项目状态:
    已结题

项目摘要

The specific aims of this proposed supplement reflect the original aims of grant DA-10337, funded in June of 1996: (1) Using ribozyme motifs known to function in mammalian cells, we will develop a set of targeted ribozymes and external guide sequences (EGSs) to achieve cleavage of the DOR and NMDA receptor mRNAs. In the supplementary work, we will expand this approach to sites in HIV mRNA sequences which can be cleaved by the ribozyme approach. (2) In both the original and supplementary work, we will test and compare these ribozyme and EGS elements in test tube experiments, using both purified components and subcellular extracts, in order to selected the most promising candidates for introduction into cells. In contrast to the approach with the cellular receptor mRNAs, we will emphasize ribozyme motifs and guide sequence targeted to HIV mRNA which can be synthesized chemically and delivered to cells without the use of vectors. (3) In original proposal for a three-year study, we planned to introduce sequences encoding ribozyme and EGS motifs into the cellular environment, using a retroviral vector system and the cultured neuroblastoma cell line NG108-15, and these experiments remain on track. However, it is unlikely that the research period of the supplement (less than two years) will allow this aim to be pursued in the case of HIV anti-viral ribozymes for the direct uptake of synthetic RNAs by cells and their transport to the nucleus. As in the original research, we will take advantage of the techniques for RNA quantitation which have been worked out over the past several years in the Robertson and Inturrisi laboratories. The long-term goal of these experiments is to reach the point where these ribozymes elements derived from human cells can be introduced into cells and animals, in order to compare their effectiveness in achieving anti-HIV effects, with those obtainable by techniques using DNA antisense oligonucleotides or vector-drive delivery of ribozymes from the plant kingdom.
这一拟议补编的具体目标反映了

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HUGH D ROBERTSON其他文献

HUGH D ROBERTSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HUGH D ROBERTSON', 18)}}的其他基金

HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY
HCV 内部核糖体进入位点作为治疗靶点
  • 批准号:
    2906461
  • 财政年份:
    1999
  • 资助金额:
    $ 26.09万
  • 项目类别:
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY
HCV 内部核糖体进入位点作为治疗靶点
  • 批准号:
    6524545
  • 财政年份:
    1999
  • 资助金额:
    $ 26.09万
  • 项目类别:
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY
HCV 内部核糖体进入位点作为治疗靶点
  • 批准号:
    6381649
  • 财政年份:
    1999
  • 资助金额:
    $ 26.09万
  • 项目类别:
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY
HCV 内部核糖体进入位点作为治疗靶点
  • 批准号:
    6177909
  • 财政年份:
    1999
  • 资助金额:
    $ 26.09万
  • 项目类别:
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY
HCV 内部核糖体进入位点作为治疗靶点
  • 批准号:
    6630532
  • 财政年份:
    1999
  • 资助金额:
    $ 26.09万
  • 项目类别:
MODULATION OF OPIOID AND NMDA RECEPTOR MRNA BY RIBOZYMES
核酶对阿片类药物和 NMDA 受体 mRNA 的调节
  • 批准号:
    2544656
  • 财政年份:
    1996
  • 资助金额:
    $ 26.09万
  • 项目类别:
MODULATION OF OPIOID AND NMDA RECEPTOR MRNA BY RIBOZYMES
核酶对阿片类药物和 NMDA 受体 mRNA 的调节
  • 批准号:
    2414623
  • 财政年份:
    1996
  • 资助金额:
    $ 26.09万
  • 项目类别:
MODULATION OF OPIOID AND NMDA RECEPTOR MRNA BY RIBOZYMES
核酶对阿片类药物和 NMDA 受体 mRNA 的调节
  • 批准号:
    2123782
  • 财政年份:
    1996
  • 资助金额:
    $ 26.09万
  • 项目类别:
MOLECULAR BIOLOGY OF THE DELTA AGENT
Delta Agent 的分子生物学
  • 批准号:
    2066065
  • 财政年份:
    1992
  • 资助金额:
    $ 26.09万
  • 项目类别:
MOLECULAR BIOLOGY OF THE DELTA AGENT
Delta Agent 的分子生物学
  • 批准号:
    3146056
  • 财政年份:
    1992
  • 资助金额:
    $ 26.09万
  • 项目类别:

相似海外基金

ACTG 303--RISK STATUS FOR DISEASE PROGRESSION AND RESPONSE TO ANTIAIDS AGENT
ACTG 303--疾病进展的风险状态和抗艾滋病药物的反应
  • 批准号:
    6114298
  • 财政年份:
    1998
  • 资助金额:
    $ 26.09万
  • 项目类别:
ACTG 303--RISK STATUS FOR DISEASE PROGRESSION AND RESPONSE TO ANTIAIDS AGENT
ACTG 303--疾病进展的风险状态和抗艾滋病药物的反应
  • 批准号:
    6275533
  • 财政年份:
    1997
  • 资助金额:
    $ 26.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了